海外有望企業情報SequestBio

SequestOne(TM)は、臨床・分子・トランスクリプトミクスデータを統合し、乳がん患者の転移リスクを高精度で予測するSaMD。量子対応AIモデルにより、多様な患者に対し、腫瘍微小環境の相互作用をモデル化することで治療方針の意思決定を支援。マルチモーダルデータ統合、説明可能なAI、量子アーキテクチャが同SaMDの競争優位性である。

SequestOn(TM), is a software-as-a-medical-device (SaMD) that integrates clinical, molecular, and transcriptomic data to accurately predict metastatic risk in breast cancer patients. SequestOne leverages advanced AI models enhanced with quantum-ready algorithms, enabling superior performance and scalability across diverse patient populations. The platform not only predicts metastasis with high accuracy but also provides actionable insights to guide therapy decisions by modeling tumor–microenvironment interactions. Competitive advantages include its multi-modal data integration, explainable AI framework, and future-proof quantum architecture, which collectively set it apart from current standards of care.